EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Long‐Term, but Not Short‐Term TLR2 Priming of Gingival Fibroblasts Inhibits Osteoclast Formation

Lidia Bulatova, Daphne V. Tilleman, Jolanda M. A. Hogervorst, Ton Schoenmaker, Teun J. de Vries

APMIS · 2026-11 · 134 (11)

DOI: 10.1111/apm.70277 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT A key event of the chronic inflammatory disease periodontitis is the frequent and repeated exposure of periodontal tissues to products from periodontopathogens. To analyse the effect of such priming, this study investigated to what extent short‐term and long‐term Toll‐like receptor 2 (TLR2) agonist priming and repriming of gingival fibroblasts (GF) regulated osteogenesis and osteoclastogenesis. Given the well‐known stimulatory effect of inflammatory cytokines on osteoclast formation, we hypothesised that any exposure of GF to TLR2 agonist will enhance osteoclast formation. Short‐term priming (24 h) induced a pro‐inflammatory gene expression profile, with increased IL‐6 expression and downregulation of TLR2, but did not alter osteoclastogenesis. In contrast, long‐term priming of 1 week inhibited the formation of osteoclasts. M‐CSF protein decreased and OPG increased. Repriming caused an increase in expression of IL‐8 and TNF‐α. This effect was visible after co‐culturing with peripheral blood mononuclear cells for 14 days after the initial priming of the fibroblasts, indicating that (re‐)priming may result in long‐lasting effects. Osteogenesis was relatively unresponsive to TLR2 agonist priming when measuring alkaline phosphatase (ALP) and with heterogenic responses after Alizarin Red staining. These findings suggest that the timing and duration of TLR2 priming potentially reprograms GF function, primarily inhibiting osteoclast formation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →